- Update on emerging PROTACs, molecular glues, and new degrader modalities
- Chasing new intracellular and extracellular drug targets
- Design, characterization, and optimization of degraders and glues
- Finding new E3ligases for targeted degradation
- New screening approaches to identify and optimize novel degraders
- Tackling issues surrounding dosing, stability, biodistribution, tissue penetration, and more
- Predicting and optimizing in vivo degrader specificity and safety
Next-Generation Degraders & Glues 2022 London United Kingdom
The 2nd Annual conference on Next-Generation Degraders & Glues brings together experts in the field to discuss the new therapeutic modalities detailed below, as well as issues underlying the use of targeted degradation as a new therapeutic approach.
The ubiquitin-proteasome, lysosome, and autophagy systems are all well-controlled, selective degradation pathways that are key cellular regulators in cancer, CNS, and other diseases. A new generation of hetero bi-functional chimeras and small molecule monovalent degraders are being developed to hijack these systems for targeted protein degradation or stabilization. These molecules that include Proteolysis-targeting chimeras (PROTACs) and molecular glues are being used to seek out previously “undruggable” targets for therapeutic intervention. However, challenges do exist in terms of specificity, stability, biodistribution, and penetration of these degrader molecules.
Submit a speaker proposal, register, or become a sponsor!
, 
, 
, 
, 
, 
